Nanopublications

@prefix dc1: <http://purl.org/dc/terms/> .
@prefix this: <http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo> .
@prefix sub: <http://purl.org/np/RAMDo1uV4osMyL1h1sdF7oV__yeXMqzIrnLlN3kjAwimo#> .
@prefix schema: <https://schema.org/> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix nt: <https://w3id.org/np/o/ntemplate/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix orcid: <https://orcid.org/> .
@prefix bl: <https://w3id.org/biolink/vocab/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion ;
    np:hasProvenance sub:provenance ;
    np:hasPublicationInfo sub:pubinfo ;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_5419> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_5419> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01224> ;
    a rdf:Statement ;
    rdfs:label "seroquel xr is an atypical antipsychotic indicated for the treatment of schizophrenia 1 1 adults efficacy was established with seroquel xr in one 6 week and one maintenance trial in patients with schizophrenia as well as in three 6 week trials with seroquel in patients with schizophrenia 14 1 acute treatment of manic or mixed episodes associated with bipolar i disorder both as monotherapy and as an adjunct to lithium or divalproex 1 2 adults efficacy was established with seroquel xr in one 3 week trial in patients with manic or mixed episodes associated with bipolar i disorder as well as two 12 week monotherapy trials and one 3 week adjunctive trial with seroquel in patients with manic episodes associated with bipolar i disorder 14 2 acute treatment of depressive episodes associated with bipolar disorder 1 2 adults efficacy was established with seroquel xr in one 8 week trial in patients with bipolar i or ii disorder as well as two 8 week trials with seroquel in patients with bipolar i or ii disorder 14 2 maintenance treatment of bipolar i disorder as an adjunct to lithium or divalproex 1 2 adults efficacy was established with seroquel in two maintenance trials in patients with bipolar i disorder 14 2 adjunctive treatment of major depressive disorder mdd 1 3 adults efficacy as an adjunct to antidepressants was established in two 6 week trials in patients with mdd who had an inadequate response to an antidepressant alone 14 3 seroquel xr is indicated for the treatment of schizophrenia the efficacy of seroquel xr in schizophrenia was established in one 6 week and one maintenance trial in adults with schizophrenia as well by extrapolation from three 6 week trials in adults with schizophrenia treated with seroquel see clinical studies seroquel xr is indicated for the acute treatment of manic or mixed episodes associated with bipolar i disorder both as monotherapy and as an adjunct to lithium or divalproex the efficacy of seroquel xr in manic or mixed episodes of bipolar i disorder was established in one 3 week trial in adults with manic or mixed episodes associated with bipolar i disorder as well by extrapolation from two 12 week monotherapy and one 3 week adjunctive trial in adults with manic episodes associated with bipolar i disorder treated with seroquel see clinical studies seroquel xr is indicated for the acute treatment of depressive episodes associated with bipolar disorder the efficacy of seroquel xr was established in one 8 week trial in adults with bipolar i or ii disorder as well as extrapolation from two 8 week trials in adults with bipolar i or ii disorder treated with seroquel see clinical studies seroquel xr is indicated for the maintenance treatment of bipolar i disorder as an adjunct to lithium or divalproex efficacy was extrapolated from two maintenance trials in adults with bipolar i disorder treated with seroquel the effectiveness of monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials see clinical studies seroquel xr is indicated for use as adjunctive therapy to antidepressants for the treatment of mdd the efficacy of seroquel xr as adjunctive therapy to antidepressants in mdd was established in two 6 week trials in adults with mdd who had an inadequate response to antidepressant treatment see clinical studies" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation schema:TreatmentIndication .
  <https://identifiers.org/drugbank:DB01224> bl:category bl:Drug .
}

sub:provenance {
sub:assertion prov:wasAttributedTo orcid:0000-0002-1468-3557 .
}

sub:pubinfo {
  sub:sig npx:hasAlgorithm "RSA" ;
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" ;
    npx:hasSignature "P8jfgkiIpRZeMDXhKrcvfV+VkFTJk/0huU+lXWmZn2lPfgc8O+3viHV5lstMrJfpGYgQSonpW0OEAlfdf4SXyZBEKa2kJkBaO7//iXejd/nMoIO6SP+yyYtitqiWUPzXLLgseUo0r4y5RfrmSIWa/83YF9m+s83muq96Yzk6nDs=" ;
    npx:hasSignatureTarget this: .
  this: dc1:created "2021-06-13T16:05:50.956+02:00"^^xsd:dateTime ;
    dc1:creator orcid:0000-0002-1468-3557 ;
    nt:wasCreatedFromProvenanceTemplate <http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM> ;
    nt:wasCreatedFromPubinfoTemplate <http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM> ;
    nt:wasCreatedFromTemplate <http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs> .
}